Theorem Adds RadMD to its Roster of Strategic Alliances
News Aug 16, 2013
Theorem Clinical Research has announced the addition of RadMD, a cutting-edge medical imaging expertise company, to its roster of strategic alliances.
“These kinds of alliances allow us to extend our capabilities to offer a greater depth and spectrum of services to our clients,” said D. Lee Spurgin Jr., Ph.D., Theorem senior vice president and general manager of medical device and diagnostic development.
Spurgin continued, “When we work with partners that we already know and trust, we feel our clients get a better end result.”
With the increasing utilization of imaging in clinical research, there has been a greater demand for expertise on the use of medical imaging in clinical trials.
RadMD offers unique services centered solely on the use of imaging in trials. They provide a consultative approach to implementing medical imaging endpoints based on extensive experience in the pharmaceutical development of both diagnostic and therapeutic drugs.
RadMD’s services include expertise in constructing customized medical imaging solutions, a unique worldwide network of more than 600 physicians and medical imaging experts available for independent image evaluations or “blinded reads”, regulatory strategy, imaging endpoint justification and extensive imaging training capabilities.
“We are excited to be able to bring our imaging expertise in clinical development to Theorem’s clientele, and look forward to working together to develop innovative products for our mutual customers and patients,” said Doug Stefanelli RadMD COO and executive vice president.
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018